Abstract
Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.
| Original language | English |
|---|---|
| Pages (from-to) | 805-809 |
| Number of pages | 5 |
| Journal | Journal of Endourology |
| Volume | 24 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2010 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Prostate cancer : An evolving paradigm. / Caso, Jorge R.; Mouraviev, Vladimir; Tsivian, Matvey; Polascik, Thomas J.; Moul, Judd W.
In: Journal of Endourology, Vol. 24, No. 5, 01.05.2010, p. 805-809.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prostate cancer
T2 - An evolving paradigm
AU - Caso, Jorge R.
AU - Mouraviev, Vladimir
AU - Tsivian, Matvey
AU - Polascik, Thomas J.
AU - Moul, Judd W.
PY - 2010/5/1
Y1 - 2010/5/1
N2 - Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.
AB - Since at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have decreased significantly. These improved prognostic variables have led to a larger portion of men being stratified with low-risk disease, as per the classification of D'Amico and associates. This, in turn, has corresponded with more favorable postoperative variables, including decreased extraprostatic tumor extension and prolonged biochemical-free recurrence rates. The advent of focal therapy is bolstered by findings of increased unilateral disease with decreased tumor volume. Increasingly, targeted or delayed therapies may be possible within the current era of lower risk disease.
UR - http://www.scopus.com/inward/record.url?scp=77952554715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952554715&partnerID=8YFLogxK
U2 - 10.1089/end.2009.0539
DO - 10.1089/end.2009.0539
M3 - Article
VL - 24
SP - 805
EP - 809
JO - Journal of Endourology
JF - Journal of Endourology
SN - 0892-7790
IS - 5
ER -